<DOC>
	<DOCNO>NCT02172001</DOCNO>
	<brief_summary>The primary objective study evaluate compare effect iron isomaltoside 1000 placebo ability increase haemoglobin ( Hb ) subject IDA oral iron preparation ineffective use .</brief_summary>
	<brief_title>A Randomized , Double-blind , Comparative Study Intravenous Iron Isomaltoside 1000 ( Monofer® ) Against Placebo</brief_title>
	<detailed_description>IDA highly prevalent subject substantial medical quality life ( QoL ) burden subject treatment subject include replenish lose iron . Oral iron administration often use clinical practice many clinic ; however , oral iron may tolerate subject . Hence , need alternative iron treatment subject , tolerate oral iron . This study plan compare efficacy safety iron isomaltoside 1000 placebo subject IDA intolerant unresponsive oral iron therapy..</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Men woman ≥ 18 year IDA cause different aetiologies* abnormal uterine bleeding , gastrointestinal disease ( e.g . inflammatory bowel disease ) , cancer , preoperative anaemia ( e.g . orthopaedic surgery ) , condition lead IDA document history intolerance unresponsiveness oral iron therapy** least one month*** prior study enrolment 2 . Hb &lt; 11 g/dL 3 . TSAT &lt; 20 % 4 . Sferritin &lt; 100 ng/mL 5 . Willingness participate signing informed consent form ( ICF ) 1 . Hb &lt; 6 g/dL 2 . Anaemia predominantly cause factor IDA ( e.g . anaemia untreated vitamin B12 folate deficiency , haemolytic anaemia ) 3 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 4 . Decompensated liver cirrhosis active hepatitis ( ALAT &gt; 3 time upper limit normal ) 5 . Active acute chronic infection ( assessed clinical judgement supply white blood cell ( WBC ) Creactive protein ( CRP ) ) 6 . Body weight &lt; 50 kg 7 . Pregnant nursing woman . In order avoid pregnancy , woman childbearing potential use adequate contraception ( e.g . intrauterine device , hormonal contraceptive , double barrier method ) whole study period 7 day last dosing 8 . History multiple allergy 9 . Known hypersensitivity parenteral iron excipients investigational drug product 10 . Erythropoietin treatment within 8 week prior screen visit 11 . Other intravenous ( IV ) iron treatment blood transfusion within 4 week prior screen visit 12 . Participation interventional clinical study within 3 month prior screen 13 . Any medical condition , opinion Investigator , may cause subject unsuitable completion study place subject potential risk study , e.g . uncontrolled hypertension , unstable ischemic heart disease , uncontrolled diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>IDA</keyword>
	<keyword>Iron deficiency</keyword>
	<keyword>iron deficiency anemia intolerant unresponsive oral iron therapy</keyword>
</DOC>